NovaCardia & Domain: New-Model Spec Pharma Investing
This article was originally published in Start Up
Executive Summary
Domain partner Eckard Weber has become a master of the one-two punch in venture investing. The process (now in its third iteration following Merck's $350 million acquisition of NovaCardia): find a drug no one cares about; create a low-infrastructure company around it; find a second drug; sell off the lead drug through an acquisition; develop the second drug a bit more with the same management; then sell that one too. The first deal at a minimum pays back the investors; the second deal juices the returns. It's a model many VCs want to follow.
You may also be interested in...
Where Are They Now? Checking In On Four Cardiovascular Start-Ups
It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.
Merck’s Heart Failure Drug Flunks Phase III
Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.
Merck’s Heart Failure Drug Flunks Phase III
Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.